MwanzoTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Bei iliyotangulia
$ 3.72
Bei za siku
$ 3.62 - $ 3.76
Bei za mwaka
$ 3.03 - $ 14.80
Thamani ya kampuni katika soko
3.44M USD
Wastani wa hisa zilizouzwa
elfu 28.06
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | elfu 666.00 | -53.88% |
Mapato halisi | elfu -790.00 | 59.90% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | — | — |
EBITDA | elfu -666.00 | 65.46% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 2.83M | -58.12% |
Jumla ya mali | 2.92M | -63.85% |
Jumla ya dhima | elfu 483.00 | -66.55% |
Jumla ya hisa | 2.44M | — |
hisa zilizosalia | elfu 914.23 | — |
Uwiano wa bei na thamani | 1.39 | — |
Faida inayotokana na mali | -51.03% | — |
Faida inayotokana mtaji | -58.72% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | elfu -790.00 | 59.90% |
Pesa kutokana na shughuli | elfu -506.00 | 77.47% |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | elfu -62.00 | -115.27% |
Mabadiliko halisi ya pesa taslimu | elfu -568.00 | 57.49% |
Mtiririko huru wa pesa | elfu -193.25 | 80.89% |
Kuhusu
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Ilianzishwa
1991
Makao Makuu
Tovuti
Wafanyakazi
4
